Business Context and Reporting Period
Company: Can-Fite Biopharma Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Period: Unaudited interim condensed consolidated financial statements as of June 30, 2019.
Filing Date: August 30, 2019.
Key Financial Metrics
The provided text serves as a cover sheet and exhibit index for the Form 6-K. It references the existence of financial statements (Exhibit 99.2) and an operating review (Exhibit 99.1) but does not contain the actual numerical data.
- Revenue, Profit, Cash Flow, Margins: The filing text does not provide a clear value.
- Debt and Liquidity: The filing text does not provide a clear value.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. Specific operational or financial comparisons are contained within the referenced exhibits (99.1 and 99.2) which are not included in the input text.
Guidance, Outlook, and Risks
The filing references an "Operating and Financial Review and Prospects" in Exhibit 99.1, but the specific content regarding guidance, management commentary, risks, contingencies, or unusual items is not present in the provided text.
Investor Verification Checklist
- Review Exhibit 99.2 for specific revenue, net loss, and cash burn rates for the six months ended June 30, 2019.
- Examine Exhibit 99.1 for management's discussion of clinical trial progress and future capital requirements.
- Verify the company's cash runway and liquidity position as of the reporting date.
- Confirm any updates to the development timeline for the company's lead drug candidates.